{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:36:18Z","timestamp":1794353778431,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004835","name":"Zhejiang University","doi-asserted-by":"publisher","award":["2025YQ005"],"award-info":[{"award-number":["2025YQ005"]}],"id":[{"id":"10.13039\/501100004835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020760","name":"Sanya Yazhou Bay Science and Technology City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008111","name":"Hainan Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["ZDYF2025SHFZ053"],"award-info":[{"award-number":["ZDYF2025SHFZ053"]}],"id":[{"id":"10.13039\/501100008111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008111","name":"Hainan Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["820LH034"],"award-info":[{"award-number":["820LH034"]}],"id":[{"id":"10.13039\/501100008111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejmech.2026.118573","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T16:21:34Z","timestamp":1768234894000},"page":"118573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancer"],"prefix":"10.1016","volume":"305","author":[{"given":"Zhangyun","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Churu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-3331","authenticated-orcid":false,"given":"Wanjing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118573_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2026.118573_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118573_bib3","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/bjs.9225","article-title":"Extent and completeness of mesorectal excision evaluated by postoperative magnetic resonance imaging","volume":"100","author":"Bondeven","year":"2013","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.ejmech.2026.118573_bib4","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118573_bib5","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ijc.30805","article-title":"What has preoperative radio(chemo)therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients","volume":"141","author":"Ma","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118573_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2014.05.010","article-title":"Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy","volume":"92","author":"Marino","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.118573_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.clon.2017.03.001","article-title":"Adjuvant chemotherapy for stage II and III Colon cancer following complete resection: a cancer care Ontario systematic review","volume":"29","author":"Meyers","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118573_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.118573_bib9","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS Wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118573_bib10","first-page":"e12","article-title":"Current microsatellite instability testing in management of colorectal cancer, clin","volume":"20","author":"Sun","year":"2021","journal-title":"Colorectal Cancer"},{"key":"10.1016\/j.ejmech.2026.118573_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.canlet.2017.03.023","article-title":"Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer","volume":"396","author":"Koustas","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118573_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature10212","article-title":"Microenvironmental regulation of stem cells in intestinal homeostasis and cancer","volume":"474","author":"Medema","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118573_bib13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118573_bib14","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1093\/emboj\/19.22.6141","article-title":"The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p","volume":"19","author":"Owen","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.118573_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2026.118573_bib16","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1016\/j.molcel.2023.10.004","article-title":"Transcriptional elongation control in developmental gene expression, aging, and disease","volume":"83","author":"Aoi","year":"2023","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2026.118573_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molcel.2014.05.018","article-title":"Chromatin reader Brd4 functions in Ig class switching as a repair complex adaptor of nonhomologous end-joining","volume":"55","author":"Stanlie","year":"2014","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2026.118573_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00109-011-0837-0","article-title":"Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer","volume":"90","author":"Rodriguez","year":"2012","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejmech.2026.118573_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jconrel.2022.12.035","article-title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy","volume":"354","author":"He","year":"2023","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejmech.2026.118573_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.aao2793","article-title":"SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis","volume":"360","author":"Muhar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118573_bib21","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011","article-title":"Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors","volume":"23","author":"Ramadoss","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.118573_bib22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/ijms16011928","article-title":"BRD4 inhibitor inhibits colorectal cancer growth and metastasis","volume":"16","author":"Hu","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118573_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.118573_bib24","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41388-025-03453-6","article-title":"BRD4 regulates PAI-1 expression in tumor-associated macrophages to drive chemoresistance in colorectal cancer","volume":"44","author":"Pan","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118573_bib25","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118573_bib26","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains","volume":"56","author":"Mirguet","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118573_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118573_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118573_bib29","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","article-title":"A potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor","volume":"60","author":"McDaniel","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118573_bib30","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-Human study of mivebresib (ABBV-075), an oral pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed\/refractory solid tumors","volume":"25","author":"Piha-Paul","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118573_bib31","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-16-0141","article-title":"AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies","volume":"15","author":"Rhyasen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2026.118573_bib32","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.1038\/s41598-017-08909-8","article-title":"Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118573_bib33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10557-012-6373-5","article-title":"ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies","volume":"26","author":"Nicholls","year":"2012","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ejmech.2026.118573_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-023-00696-6","article-title":"Pelabresib (CPI-0610): an exciting novel drug for the treatment of myelofibrosis","volume":"18","author":"Ferreira Gomes","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.ejmech.2026.118573_bib35","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118573_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118573_bib37","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","article-title":"Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118573_bib38","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2026.118573_bib39","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","article-title":"Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study","volume":"3","author":"Amorim","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ejmech.2026.118573_bib40","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/s41416-021-01321-0","article-title":"Achieving clinical success with BET inhibitors as anti-cancer agents","volume":"124","author":"Shorstova","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118573_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107479","article-title":"Make your best BET: the emerging role of BET inhibitor treatment in malignant tumors","volume":"208","author":"Bechter","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118573_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118573_bib43","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1158\/0008-5472.CAN-05-4412","article-title":"Bcl-2 inhibition of autophagy: a new route to cancer?","volume":"66","author":"Pattingre","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118573_bib44","doi-asserted-by":"crossref","first-page":"32628","DOI":"10.18632\/oncotarget.8701","article-title":"Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer","volume":"7","author":"Hong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.118573_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg5109","article-title":"Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription","volume":"9","author":"Cameron","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118573_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2023.142356","article-title":"Development of a sensitive luminescent probe to uncover new BRD4 inhibitors in living cells","volume":"463","author":"Song","year":"2023","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejmech.2026.118573_bib47","doi-asserted-by":"crossref","first-page":"12156","DOI":"10.1021\/acs.jmedchem.9b01813","article-title":"Integrating the impact of lipophilicity on potency and pharmacokinetic parameters enables the use of diverse chemical space during small molecule drug optimization","volume":"63","author":"Miller","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118573_bib48","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118573_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tips.2016.05.006","article-title":"Recent structural insights into cytochrome P450 function","volume":"37","author":"Guengerich","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118573_bib50","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1073\/pnas.050586197","article-title":"Identification of CDK4 as a target of c-MYC","volume":"97","author":"Hermeking","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.118573_bib51","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.gendis.2020.08.001","article-title":"PTPN18 promotes colorectal cancer progression by regulating the c-MYC-CDK4 axis","volume":"8","author":"Li","year":"2021","journal-title":"Genes Dis."},{"key":"10.1016\/j.ejmech.2026.118573_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22062841","article-title":"Co-Operativity between MYC and BCL-2 pro-survival proteins in cancer","volume":"22","author":"Fairlie","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118573_bib53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41419-021-03722-8","article-title":"YAP inhibits autophagy and promotes progression of colorectal cancer via upregulating Bcl-2 expression","volume":"12","author":"Jin","year":"2021","journal-title":"Cell Death Dis."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:01:16Z","timestamp":1773961276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S0223523426000188"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118573","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of an orally bioavailable pyridone-based BRD4 inhibitor with potent antitumor efficacy in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118573"}}